Clinical Trials Logo

Clinical Trial Summary

Aprepitant and olanzapine have been recommended for emesis prevention from highly emetogenic chemotherapy. We hypothesized that olanzapine may lead to less nausea compared to aprepitant based on previous study. However, data of combination of olanzapine and ondansetron is scarce.


Clinical Trial Description

Aprepitant and olanzapine have been recommended for emesis prevention from highly emetogenic chemotherapy. We hypothesized that olanzapine may lead to less nausea compared to aprepitant based on previous study. However, data on efficacy and adverse effects of combination of olanzapine and ondansetron which is only serotonin antagonist in Thai national essential drug list, is scarce. Also, we aims to assess the efficacy of olanzapine dosage of 5 mg which is more commonly used in Thai patients. ;


Study Design


Related Conditions & MeSH terms

  • Antiemetic for Highly Emetogenic Chemotherapy

NCT number NCT03876938
Study type Interventional
Source Mahidol University
Contact Suthinee Ithimakin, MD
Phone +6624194489
Email aesi105@yahoo.co.th
Status Recruiting
Phase Phase 3
Start date March 1, 2019
Completion date December 2020